Hero Image

A Clear Guide to Stem Cell Therapy for COPD

Considering stem cell therapy for COPD?

This clear, research-based guide explains what it is, how it’s being studied, where people access it, what it may cost, and how to decide—together with your clinician—if it makes sense for you.

Note: This article is educational and not a substitute for personal medical advice. Always review options with a qualified pulmonologist who knows your history.

What is stem cell therapy for COPD?

Stem cells are special cells that can self-renew and, under the right conditions, become other cell types. In chronic obstructive pulmonary disease (COPD)—a progressive condition that restricts airflow—researchers are exploring whether certain stem cells, most often mesenchymal stromal/stem cells (MSCs), can calm harmful inflammation or support repair of damaged lung tissue. For a refresher on COPD basics, see the NHLBI overview.

In studies, cells are typically sourced from a person’s own tissue (autologous, e.g., bone marrow or adipose) or a donor (allogeneic, often umbilical cord tissue). They’re delivered via intravenous (IV) infusion and, in some trials, directly into the airways. The proposed actions include immunomodulation and tissue support—not “growing new lungs,” which current science cannot do.

It’s also critical to understand the regulatory status. In the United States, there are no FDA‑approved stem cell therapies for COPD at this time. The FDA urges caution about clinics marketing unproven products outside clinical trials; see the consumer advisory, “Beware of Stem Cell Therapies.”

What does the evidence show so far?

Early-phase studies suggest that MSC infusions are feasible and generally well tolerated in the short term for many participants. Some trials report modest improvements in symptoms, six‑minute walk distance, or health-related quality of life. However, study sizes are small, methods vary widely, and results are mixed.

  • Efficacy remains unproven. There is not yet robust evidence that stem cell therapy can reverse COPD or reliably improve lung function (e.g., FEV1) beyond standard care.
  • High heterogeneity. Outcomes differ by cell source, dose, delivery route, and who is enrolled, making comparisons difficult.
  • Unknown long‑term safety. Most studies follow patients for months, not years; larger, longer, placebo‑controlled trials are needed.
  • Guidelines are cautious. Leading recommendations, such as the GOLD report, do not advise routine use outside research settings.

Potential benefits and risks

Potential benefits (under study)

  • Reduced airway and systemic inflammation
  • Improved symptoms, such as breathlessness or fatigue
  • Better exercise capacity and quality‑of‑life scores
  • Fewer exacerbations (still uncertain and under investigation)

Risks and limitations

  • Regulatory risk: Receiving unapproved therapy outside a legitimate clinical trial may expose you to unproven products.
  • Medical risks: Infection, infusion reactions, clotting issues, allergic or immune reactions, and unknown long‑term effects.
  • Financial risk: Out‑of‑pocket costs are substantial; insurance generally does not cover non‑approved treatments.
  • Opportunity cost: Time and money spent on unproven therapy may delay proven COPD care.

Who might consider it—and who shouldn’t

If you have moderate to very severe COPD and remain highly symptomatic despite optimized, guideline‑based care, you may be curious about stem cells. Candidates for clinical trials typically include adults with confirmed COPD who are stable on medications and meet specific safety and lung function criteria. Your pulmonologist can help you decide whether you’re a potential fit for a study.

Conversely, those with uncontrolled infections, active cancer, severe heart or bleeding disorders, or other exclusion conditions may not qualify. If you’re eligible for proven interventions—such as inhaler optimization, pulmonary rehabilitation, long‑term oxygen therapy, lung volume reduction options, or transplant evaluation—these should be carefully weighed first in line with GOLD guidance.

Where to find stem cell therapy for COPD

Start with clinical trials

The safest, most transparent path is a regulated clinical trial at an academic or research center. Search ClinicalTrials.gov for COPD stem cell trials and ask your pulmonologist about eligibility. You can also explore research opportunities and updates from the COPD Foundation.

Be cautious with private clinics

Some clinics in the U.S. and abroad market stem cell therapy for COPD outside of trials. If you consider this route, use the International Society for Stem Cell Research resource, A Closer Look at Stem Cells, to vet claims and understand red flags. In the U.S., ask providers for an FDA Investigational New Drug (IND) number and IRB approval details, and compare safety claims with peer‑reviewed publications—not testimonials. When in doubt, review the FDA’s advisory on unproven stem cell therapies.

How much does it cost?

Costs vary widely by country, clinic, cell source, dose, number of sessions, and whether care is provided in a clinical trial.

  • In clinical trials: Study‑related costs are often covered, though travel and lodging may not be. Medicare may cover routine costs for qualifying research; see Medicare’s clinical research policy.
  • In private clinics: Self‑pay packages in the U.S. commonly quote several thousand dollars per infusion, with multi‑session protocols reaching five figures or more. International options can be similar or higher once travel, accommodations, and follow‑up are included.

Consider the full cost picture

  • Treatment fees (consults, labs, imaging, infusion room, monitoring)
  • Travel and lodging; review the CDC’s medical tourism guidance if traveling for care
  • Time off work and caregiver support
  • Potential need for repeat sessions or additional medications
  • Emergency or complication care (rare but potentially expensive)

How to know if you need it

There’s no universal threshold that means you “need” stem cell therapy for COPD. Instead, use a stepwise approach with your clinician to clarify goals and options.

  • Optimize proven care first: Confirm correct inhaler technique and regimen, stop smoking if applicable, and prioritize vaccinations and pulmonary rehab. See resources for pulmonary rehabilitation, smoking cessation, and vaccines for people with lung disease.
  • Assess severity and goals: Discuss symptoms, exacerbation history, spirometry results, six‑minute walk distance, and oxygen needs. Be clear about what matters most (e.g., fewer flare‑ups, walking farther, maintaining independence).
  • Review advanced options: Consider oxygen therapy, lung volume reduction procedures, or transplant evaluation when appropriate, in line with GOLD recommendations.
  • Explore clinical trials: If you meet criteria and want to contribute to research, trials are the most responsible way to access experimental therapies like stem cells.
  • If considering a clinic: Proceed only after a thorough risk‑benefit discussion with your pulmonologist and careful vetting of the provider’s evidence, regulatory status, and emergency plans.

Smart questions to ask any provider

  • Is this part of a registered clinical trial? If yes, what is the ClinicalTrials.gov identifier?
  • Do you have FDA IND authorization and IRB approval? May I see the documentation?
  • What cell type, dose, and delivery route are used—and why?
  • What outcomes have you measured in prior patients, and are results published in peer‑reviewed journals?
  • What are the expected benefits, common side effects, and rare but serious risks?
  • If a complication occurs, where will I be treated and who is responsible for the cost?
  • What is the total price, including follow‑up? Are refunds or guarantees offered?

Bottom line

Stem cell therapy for COPD is a promising research area, but it remains experimental with uncertain benefits and unknown long‑term safety. The most responsible access today is through regulated clinical trials at reputable centers. Before spending significant money on private treatment, ensure your standard COPD care is optimized, understand the risks, and partner closely with a trusted pulmonologist.